Human epidermal growth factor receptor 2- (HER2-) positive breast cancer refers to ERBB2/neu protooncogene amplification or HER2 transmembrane receptor protein overexpression, which accounts for about 15%–20% of all breast cancers in incidence [5, 6]. This evidence concerns the gene NRP1 and breast carcinoma.